...
首页> 外文期刊>ID Cases >Fatal Coronavirus Disease 2019-associated Pulmonary Aspergillosis; A Report of Two Cases and Review of the Literature
【24h】

Fatal Coronavirus Disease 2019-associated Pulmonary Aspergillosis; A Report of Two Cases and Review of the Literature

机译:致命的冠状病毒疾病2019-相关的肺曲线病;关于两种情况的报告和对文献的审查

获取原文
           

摘要

Coronavirus Disease 2019 (COVID-19)-associated pulmonary aspergillosis is an emerging entity. We report two fatal cases of putative COVID-19-associated pulmonary aspergillosis. Both cases were diagnosed on the basis of respiratory tract cultures yielding Aspergillus species and otherwise unexplained clinical and radiological deterioration. Existing published literature on COVID-19-associated pulmonary aspergillosis indicate poor outcomes and high mortality. CAPA should be considered in patients with critical COVID-19 who have unexplained progressive respiratory failure despite optimized supportive care. Diagnostic work-up should be initiated as early as possible and should ideally include fungal cultures, galactomannan detection and Aspergillus PCR on tracheal aspirates or broncho-alveolar lavage fluid. Empiric systemic antifungal therapy may be justified in selected cases, pending diagnostic work up results. Large, multi-center studies are required to further understand the pathogenesis of invasive aspergillosis in COVID-19, and the optimal diagnostic and treatment strategies.
机译:冠状病毒疾病2019(Covid-19) - 相似的肺曲线菌病是一种新兴实体。我们报告了两个推定的Covid-19相关肺曲线症的致命病例。这两种病例都是根据呼吸道培养物的诊断,含有曲霉属物种,否则无法解释的临床和放射性劣化。现有的Covid-19相关肺曲线毒病发表的文献表明差异差和死亡率高。尽管有优化的支持性护理,但仍应考虑患有临界Covid-19的患者患者,尽管有优化的支持性。应尽早启动诊断处理,理想情况下应包括真菌培养物,半乳甘露甘露胺检测和气管血液吸气或支气管 - 肺泡灌洗液的曲霉。透析系统抗真菌疗法可能在选定的情况下合理,待诊断损失结果。需要大,多中心研究,以进一步了解Covid-19中侵袭性曲霉病的发病机制以及最佳的诊断和治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号